Unilever nears deal to merge food business with spice maker McCormick

Unilever is in advanced talks to combine its foods business with McCormick via a Reverse Morris Trust that would deliver roughly $15.7bn in cash and leave Unilever shareholders with an estimated 65% stake in the combined entity. Barclays values the food business at €28–31bn including debt; the deal would exclude certain assets (notably India), remains non‑binding and complex given McCormick's smaller size, so closure is uncertain despite potential strategic and tax benefits.

Analysis

The market reaction will be driven less by the headline transaction and more by the re-rating mechanics: a de-risked balance sheet at the parent, a chunky cash inflow, and clearer growth optics for the retained consumer-facing portfolio. Expect most of the near-term move to be driven by sentiment and multiple expansion rather than immediate EPS accretion — meaning valuation arbitrage trades (pairs/vol) will likely outperform simple directional longs.

Second-order winners include retailers and private-label suppliers that gain negotiating leverage if the combined food business streamlines SKUs and shifts promotional cadence during integration; conversely, mid-market CPGs that compete on scale for shelf space face higher customer concentration risk. Integration risk is non-trivial — supply-chain harmonization (recipes, sourcing contracts, co-manufacturing capacity) and brand rationalization can depress margins for 12–36 months post-close, creating a window for tactical shorts or hedges.

Key catalysts and failure modes: regulatory/tax certainty and the structure of the spin/merger drive timing more than commercial synergies, so monitor filings and tax opinions; activist or strategic counterproposals could reprice the story quickly. From a risk perspective, a failed transaction or a messy carve-out that preserves legacy food liabilities would likely trade the parent back to a double-digit discount to peers over months, while successful execution could compress that gap within a 6–18 month window.

Key Decisions for Investors

• Long UL via option spread (UL 12-month call spread): Buy 12-month calls and sell higher-strike calls to fund cost — target asymmetric upside of ~25–35% if the market re-rates on simplification; max loss = premium paid (~4–6% of notional). Time horizon: 6–12 months. Key exit: definitive agreement or clear regulatory sign-off.
• Relative-value pair: Long UL / Short PG (equal cash exposure) — play a re-rating of UL’s retained portfolio versus P&G’s steady-state business. Time horizon: 6–18 months. Target 15–25% relative outperformance; downside if P&G out-executes or macro hurts premium personal-care demand.
• Event-driven hedge: Buy short-dated UL calls into near-term rumored announcement windows and sell into news — capture skew and volatility compression if announcement occurs. Time horizon: days–weeks. Risk: if no deal, expect >70% time decay; size small (1–2% portfolio) and cap losses.
• Risk protection trade: Buy inexpensive tail protection on packaged-food complex (puts on a CPG basket or long-dated UL protective puts) sized to limit downside to ~6–8% of portfolio in a worst-case collapse scenario. Time horizon: 3–12 months. This is asymmetric insurance against a failed carve-out or activist-induced upheaval.